Cenicriviroc for the treatment of liver fibrosis in adults with nonalcoholic steatohepatitis: AURORA Phase 3 study design

DOI: 10.1016/j.cct.2019.105922
Contemporary Clinical Trials, 2020, 89, 105922.

#	Paper	IF	Citations
74	The pharmacological treatment of nonalcoholic fatty liver disease in children. *Expert Review of Clinical Pharmacology*, **2020**, 13, 1219-1227	3.8	2
73	The European NAFLD Registry: A real-world longitudinal cohort study of nonalcoholic fatty liver disease. *Contemporary Clinical Trials*, **2020**, 98, 106175	2.3	28
72	Common Drug Pipelines for the Treatment of Diabetic Nephropathy and Hepatopathy: Can We Kill Two Birds with One Stone?. *International Journal of Molecular Sciences*, **2020**, 21,	6.3	6
71	Evaluating the Therapeutic Potential of Cenicriviroc in the Treatment of Nonalcoholic Steatohepatitis with Fibrosis: A Brief Report on Emerging Data. *Hepatic Medicine: Evidence and Research*, **2020**, 12, 115-123	3.4	6
70	Antidiabetic Therapy in the Treatment of Nonalcoholic Steatohepatitis. *International Journal of Molecular Sciences*, **2020**, 21,	6.3	22
69	Current and new pharmacotherapy options for non-alcoholic steatohepatitis. *Expert Opinion on Pharmacotherapy*, **2020**, 21, 953-967	4	17
68	Diagnostic accuracy of FibroScan-AST score to identify non-alcoholic steatohepatitis with significant activity and fibrosis in Japanese patients with non-alcoholic fatty liver disease: Comparison between M and XL probes. *Hepatology Research*, **2020**, 50, 831-839	5.1	21
67	Roles of CCR2 and CCR5 for Hepatic Macrophage Polarization in Mice With Liver Parenchymal Cell-Specific NEMO Deletion. *Cellular and Molecular Gastroenterology and Hepatology*, **2021**, 11, 327-347	7.9	5
66	Immunological mechanisms and therapeutic targets of fatty liver diseases. *Cellular and Molecular Immunology*, **2021**, 18, 73-91	15.4	25
65	Narrative review of current and emerging pharmacological therapies for nonalcoholic steatohepatitis. *Translational Gastroenterology and Hepatology*, **2021**, 6, 60	5.2	2
64	Strategies Targeting the Innate Immune Response for the Treatment of Hepatitis C Virus-Associated Liver Fibrosis. *Drugs*, **2021**, 81, 419-443	12.1	2
63	An Update on Efficacy and Safety of Emerging Hepatic Antifibrotic Agents. *Journal of Clinical and Translational Hepatology*, **2021**, 9, 60-70	5.2	2
62	Implications of Breast Cancer Chemotherapy-Induced Inflammation on the Gut, Liver, and Central Nervous System. *Biomedicines*, **2021**, 9,	4.8	6
61	Hepatic Stellate Cell Activation and Inactivation in NASH-Fibrosis-Roles as Putative Treatment Targets?. *Biomedicines*, **2021**, 9,	4.8	9
60	Liver Fibrosis in Non-alcoholic Fatty Liver Disease: From Liver Biopsy to Non-invasive Biomarkers in Diagnosis and Treatment. *Frontiers in Medicine*, **2021**, 8, 615978	4.9	21
59	Metabolic Spectrum of Liver Failure in Type 2 Diabetes and Obesity: From NAFLD to NASH to HCC. *International Journal of Molecular Sciences*, **2021**, 22,	6.3	9
58	Non-alcoholic fatty liver disease (NAFLD)/non-alcoholic steatohepatitis (NASH)-related liver fibrosis: mechanisms, treatment and prevention. *Annals of Translational Medicine*, **2021**, 9, 729	3.2	12

57	Efficacy and Safety of Glucagon-like Peptide-1 Receptor Agonists in the Treatment of Metabolic Associated Fatty Liver Disease: A Systematic Review and Meta-analysis. *Journal of Clinical Gastroenterology*, **2021**, 55, 586-593	3	0
56	The complex link between NAFLD and type 2 diabetes mellitus - mechanisms and treatments. *Nature Reviews Gastroenterology and Hepatology*, **2021**, 18, 599-612	24.2	55
55	Lipid nanoparticle formulations for targeting leukocytes with therapeutic RNA in liver fibrosis. *Advanced Drug Delivery Reviews*, **2021**, 173, 70-88	18.5	4
54	Current and Emerging Approaches for Hepatic Fibrosis Treatment. *Gastroenterology Research and Practice*, **2021**, 2021, 6612892	2	1
53	Liver Injury and the Macrophage Issue: Molecular and Mechanistic Facts and Their Clinical Relevance. *International Journal of Molecular Sciences*, **2021**, 22,	6.3	6
52	Pharmacological Therapeutics: Current Trends for Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD).. *Journal of Clinical and Translational Hepatology*, **2021**, 9, 939-946	5.2	0
51	The Role of Innate Immune Cells in Nonalcoholic Fatty Liver Disease. *Journal of Innate Immunity*, **2021**, 1-11	6.9	3
50	Inflammatory and fibrotic mechanisms in NAFLD-Implications for new treatment strategies. *Journal of Internal Medicine*, **2021**,	10.8	6
49	Non-Alcoholic Steatohepatitis (NASH) - A Review of a Crowded Clinical Landscape, Driven by a Complex Disease. *Drug Design, Development and Therapy*, **2021**, 15, 3997-4009	4.4	9
48	Therapeutic targets, novel drugs, and delivery systems for diabetes associated NAFLD and liver fibrosis. *Advanced Drug Delivery Reviews*, **2021**, 176, 113888	18.5	6
47	Liver Fibrosis: Therapeutic Targets and Advances in Drug Therapy. *Frontiers in Cell and Developmental Biology*, **2021**, 9, 730176	5.7	13
46	Macrophage reprogramming for therapy. *Immunology*, **2021**, 163, 128-144	7.8	10
45	Loss of hepatocyte cell division leads to liver inflammation and fibrosis. *PLoS Genetics*, **2020**, 16, e1009084	4	8
44	Exosomal miRNAs as Potential Biomarkers to Monitor Phosphodiesterase 5 Inhibitor Induced Anti-Fibrotic Effects on CCl Treated Rats. *International Journal of Molecular Sciences*, **2020**, 22,	6.3	6
43	The Gut-Liver Axis in Chronic Liver Disease: A Macrophage Perspective. *Cells*, **2021**, 10,	7.9	1
42	MicroRNA-206 promotes the recruitment of CD8 T cells by driving M1 polarisation of Kupffer cells. *Gut*, **2021**,	19.2	4
41	Drugs for Non-alcoholic Steatohepatitis (NASH): Quest for the Holy Grail. *Journal of Clinical and Translational Hepatology*, **2021**, 9, 40-50	5.2	4
40	The therapeutic potential of C-C chemokine receptor antagonists in nonalcoholic steatohepatitis. *Exploration of Medicine*, **2020**, 1, 170-183	1.1	0

39	Targeting monocytes/macrophages in fibrosis and cancer diseases: Therapeutic approaches. *Pharmacology & Therapeutics*, **2021**, 108031	13.9	2
38	Hepatic Reduction in Cholesterol 25-Hydroxylase Aggravates Diet-induced Steatosis.. *Cellular and Molecular Gastroenterology and Hepatology*, **2022**,	7.9	0
37	Relaxin as an anti-fibrotic treatment: perspectives, challenges and future directions.. *Biochemical Pharmacology*, **2021**, 114884	6	1
36	Liver Fibrosis-From Mechanisms of Injury to Modulation of Disease.. *Frontiers in Medicine*, **2021**, 8, 814496	4.9	0
35	Functional Roles of Chemokine Receptor CCR2 and Its Ligands in Liver Disease.. *Frontiers in Immunology*, **2022**, 13, 812431	8.4	2
34	A two-step algorithm for the noninvasive identification of candidates for NASH clinical trials: the APRI-FAST.. *Clinical Gastroenterology and Hepatology*, **2022**,	6.9	
33	Factors That Predict the Progression of Non-alcoholic Fatty Liver Disease (NAFLD).. *Cureus*, **2021**, 13, e20776	1.2	1
32	Inflammation and Fibrogenesis in MAFLD: Role of the Hepatic Immune System.. *Frontiers in Medicine*, **2021**, 8, 781567	4.9	0
31	Nonalcoholic Fatty Liver Disease and Cardiovascular Risk: A Scientific Statement From the American Heart Association.. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2022**, 101161ATV0000000000000153	9.4	9
30	Validation of the accuracy of the FAST score for detecting patients with at-risk nonalcoholic steatohepatitis (NASH) in a North American cohort and comparison to other non-invasive algorithms.. *PLoS ONE*, **2022**, 17, e0266859	3.7	0
29	Roles of heterogenous hepatic macrophages in the progression of liver diseases.. *BMB Reports*, **2022**,	5.5	
28	Macrophages as key regulators of liver health and disease. *International Review of Cell and Molecular Biology*, **2022**,	6	1
27	Roles of heterogenous hepatic macrophages in the progression of liver diseases. *BMB Reports*, **2022**, 55, 166-174	5.5	0
26	Therapeutic advances in alcohol-associated hepatitis.. *Journal of Hepatology*, **2022**, 76, 1279-1290	13.4	0
25	Hyaluronan synthase 2, a target of miR-200c, promotes carbon tetrachloride-induced acute and chronic liver inflammation via regulation of CCL3 and CCL4. *Experimental and Molecular Medicine*,	12.8	0
24	An Update on the Chemokine System in the Development of NAFLD. *Medicina (Lithuania)*, **2022**, 58, 761	3.1	0
23	Hepatocellular Carcinoma Due to Nonalcoholic Fatty Liver Disease: Current Concepts and Future Challenges. *Journal of Hepatocellular Carcinoma*, Volume 9, 477-496	5.3	1
22	New Drugs for Hepatic Fibrosis. *Frontiers in Pharmacology*, 13,	5.6	1

21	Combined Therapy with a CCR2/CCR5 Antagonist and FGF21 Analogue Synergizes in Ameliorating Steatohepatitis and Fibrosis. *International Journal of Molecular Sciences*, **2022**, 23, 6696	6.3	1
20	Novel small synthetic HIV-1 V3 crown variants: CCR5 targeting ligands. *Journal of Biochemistry*,	3.1	
19	Rationale of using the dual chemokine receptor CCR2/CCR5 inhibitor cenicriviroc for the treatment of COVID-19. *PLoS Pathogens*, **2022**, 18, e1010547	7.6	0
18	Critical roles for CCR2 and the therapeutic potential of cenicriviroc in periodontitis: a pre-clinical study. *Journal of Clinical Periodontology*,	7.7	
17	Comprehensive molecular mechanisms and clinical therapy in nonalcoholic steatohepatitis: An overview and current perspectives. *Metabolism: Clinical and Experimental*, **2022**, 134, 155264	12.7	0
16	Loss of FOCAD, operating via the SKI messenger RNA surveillance pathway, causes a pediatric syndrome with liver cirrhosis. *Nature Genetics*,	36.3	0
15	Spezifische Therapie neue Medikamente. **2022**, 227-255		0
14	Combination strategies for pharmacologic treatment of non-alcoholic steatohepatitis. **2022**, 28, 5129-5140		0
13	Spotlight on liver macrophages for halting injury and progression in non-alcoholic fatty liver disease.		0
12	Roles of hepatic stellate cells in NAFLD: From the perspective of inflammation and fibrosis. 13,		1
11	Regulation of Progression and Resolution of Liver Fibrosis by Immune Cells.		0
10	Diagnostic and therapeutic strategies for non-alcoholic fatty liver disease. 13,		2
9	Formulating elafibranor and obeticholic acid with phospholipids decreases drug-induced association of SPARC to extracellular vesicles from LX-2 human hepatic stellate cells. **2023**, 182, 32-40		0
8	Emerging pharmacological treatment options for MAFLD. **2022**, 13, 204201882211424		0
7	Lessons on Drug Development: A Literature Review of Challenges Faced in Nonalcoholic Fatty Liver Disease (NAFLD) Clinical Trials. **2023**, 24, 158		0
6	Recent updates on targeting the molecular mediators of NAFLD. **2023**, 101, 101-124		0
5	Immune cells and their derived microRNA-enriched extracellular vesicles in nonalcoholic fatty liver diseases: Novel therapeutic targets. **2023**, 243, 108353		0
4	Non-alcoholic Fatty Liver Disease (NAFLD), Type 2 Diabetes, and Non-viral Hepatocarcinoma: Pathophysiological Mechanisms and New Therapeutic Strategies. **2023**, 11, 468		3

3	The contradictory roles of macrophages in non-alcoholic fatty liver disease and primary liver cancer□hallenges and opportunities. 10,	1
2	Emerging Therapeutic Targets for Portal Hypertension. **2023**, 22, 51-66	0
1	Patients with fibrosis from non-alcoholic steatohepatitis have heterogeneous intrahepatic macrophages and therapeutic targets.	0